Why Exascale Labs Holdings Inc.’s (XLAB) Stock Is Up 5.04%
As of Friday, September 25, Exascale Labs Holdings Inc.’s XLAB share price has surged by 5.04%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: Exascale Labs Holdings Inc. (XLAB)
Exascale Labs Holdings Inc. XLAB
$2.43
-0.15
-5.81%
September 25, 2026 4:00:00 PM
EST
Volume: 28,753
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Information Technology | IT Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Exascale Labs Holdings Inc. develops and operates AI computer infrastructure platforms. It offers graphics processing unit (GPU) cloud infrastructure, scalable GPU compute deployments, AI-ready data center solutions, system integration, GPU procurement and leasing, and full-stack orchestration. The company is based in Houston, Texas.
Commentary & Analysis
Financial Summary
| Share Statistics | XLAB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $221.6 | $914.1 | 28% |
|
| Shares Out (Mil) | na | 45.2 | na |
|
| Institutional Ownership | na | 73.9% | na |
|
| Float (Mil) | na | 39.0 | na |
|
| Beta | na | 0.92 | na |
|
| Avg Daily Volume (000s) | 55 | 603 | 28% |
|
| Price Change (52-week) |
(75.5%) | 53.5% | 9% |
|
| Growth | XLAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 8.3% | na |
|
| Net Income (5yr) | na | 4.8% | na |
|
| EPS (5yr) | na | 10.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (16.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | XLAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $13 | $576 | 10% |
|
| Net Income (TTM) (Mil) | ($9) | ($1) | 30% |
|
| EPS (TTM) | na | $0.000 | na |
|
| Operating Cash Flow (TTM) (Mil) | ($4) | $50 | 26% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $97 | 0% |
|
| Enterprise Value (Q1) (Mil) | $266 | $1,276 | 28% |
|
| Valuation | XLAB | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.26 | na |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | XLAB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 16.1% | 34.6% | 16% |
|
| Net Margin | (71.7%) | (0.2%) | 9% |
|
| ROA | (228.1%) | (0.6%) | 2% |
|
| ROE | 89.9% | 4.0% | 96% |
|
| Liabilities to Assets | 353.8% | 51.3% | 100% |
|
| F-Score | 1 | 4 | na |
|
Exascale Labs Holdings Inc. did not pass any screens on 9/25/2026.
